Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify
                   and Progress High Potential Therapeutics

PR Newswire

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi
Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that
they have entered into a collaboration to jointly investigate novel
therapeutic candidates and thereby further strengthen the Daiichi Sankyo
developmental pipeline across multiple therapeutic areas.

Virtici and Celdara Medical are affiliated, independent companies that build
and develop pipelines of high potential therapeutic assets. The collaboration
is intended to accelerate the time from discovery to development with the
potential to deliver first-in-class treatments that address significant unmet
medical needs. Funding is channeled into the most promising targets to drive
early research before moving into larger scale clinical development.

"This collaboration strengthens our ability to access potential breakthrough
innovation, and demonstrates our continued commitment to working with partners
at the forefront of science," said Mahmoud Ghazzi, M.D., Ph.D., Global Head of
Development, Daiichi Sankyo, Co. Ltd. "By augmenting in-house research and
other development avenues, these focused, exclusive, indication-targeted
partnerships can accelerate medical innovations into the clinic and ultimately
to patients."

"We are extremely pleased to be working with Daiichi Sankyo," said Neil
Fanger, Ph.D., President and Chief Executive Officer of Virtici. "Using our
unique model, infrastructure and capabilities, we can help further advance
Daiichi Sankyo's strong track record of innovative drug development. This
collaboration leverages the complementary capabilities and synergies between
our firms."

"This alliance represents a new partnership paradigm for Virtici and Celdara
Medical while validating our underlying development model. Daiichi Sankyo's
impressive capabilities, global reach, and open, collaborative culture make
them ideal partners," said Jake Reder, Ph.D., President and Chief Executive
Officer of Celdara Medical. "The team at Celdara Medical is excited to work
hand-in-hand with Daiichi Sankyo on some of the most challenging problems in
human health."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio
of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for
thrombotic disorders and focused on the discovery of novel oncology and
cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has
created a "Hybrid Business Model," which will respond to market and customer
diversity and optimize growth opportunities across the value chain. For more
information about Daiichi Sankyo, please visit www.daiichisankyo.com.

About Virtici, LLC

Founded in 2011, Virtici is a privately held product-development company
headquartered in Seattle, Washington. Virtici's mission is to improve quality
of life and save lives, and is primarily developing products to improve the
way we diagnose and treat cancer, autoimmunity, and cardiovascular/metabolic
diseases. Virtici, working closely with our affiliate Celdara Medical,
partners with inventors and their research institutions, bringing the business
and finance expertise to accelerate product development. Working with its
partners in the pharmaceutical industry, Virtici connects the entire product
development lifecycle by improving innovation, enhancing discovery and
increasing product development efficiencies. For more information about
Virtici, please visit www.virtici.com.

About Celdara Medical, LLC

Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, and
is headquartered at the Dartmouth Regional Technology Center (DRTC) in
Lebanon, NH. Celdara Medical builds academic and early-stage innovations into
high-potential medical companies, identifying discoveries of exceptional value
at the earliest stages and moving them toward the market. Celdara Medical,
working closely with our affiliate Virtici, partners with inventors and their
institutions, providing the developmental, financial, and business acumen
required to bridge discovery and profitability. With robust funding options, a
diverse and high impact Programmatic pipeline, and partnerships with
world-class academic institutions and industry leaders, Celdara Medical
navigates all aspects of a complex industry, accelerating science to improve
human health.For more information about Celdara Medical, please visit

SOURCE Daiichi Sankyo, Inc.

Website: http://www.daiichisankyo.com
Contact: Neil Fanger, Ph.D., Virtici, LLC, (206) 228-1458,
nfanger@virtici.com; Karen Hermanson, Celdara Medical, LLC, (617) 320 8521,
info@celdaramedical.com; Kimberly Wix, Daiichi Sankyo, Inc., (973) 944 2338,
Press spacebar to pause and continue. Press esc to stop.